Federal Register / Vol. 80, No. 55 / Monday, March 23, 2015 / Notices 15227 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, 

comments, and other materials relating 

to the contemplated exclusive 

evaluation option license should be 

directed to: Jennifer Wong, M.S., Senior 

Licensing and Patenting Manager, Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 435– 

4633; Facsimile: (301) 402–0220; Email: 

wongje@od.nih.gov. 

SUPPLEMENTARY INFORMATION: Tyrosine 

kinase-like orphan receptor 1 (ROR1) is 

a signature cell surface antigen for B-cell 

malignancies, most notably, B-cell 

chronic lymphocytic leukemia (B–CLL) 

and mantle cell lymphoma (MCL) cells, 

two incurable diseases. The 

investigators have developed a portfolio 

of chimeric anti-ROR1 monoclonal 

antibodies that selectively target ROR1 

malignant B-cells but not normal Bcells. These antibodies may be linked to 

chemical drugs or biological toxins thus 

providing targeted cytotoxic delivery to 

malignant B-cells while sparing normal 

cells. Moreover, as these antibodies 

selectively target ROR1, they can also be 

used to diagnose B-cell malignancies. 

The prospective start-up exclusive 

evaluation option license is being 

considered under the small business 

initiative launched on October 1, 2011 

and will comply with the terms and 

conditions of 35 U.S.C. 209 and 37 CFR 

part 404. The prospective start-up 

exclusive evaluation option license, and 

a subsequent start-up exclusive patent 

commercialization license, may be 

granted unless within fifteen (15) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404. 

Any additional, properly filed, and 

complete applications for a license in 

the field of use filed in response to this 

notice will be treated as objections to 

the grant of the contemplated start-up 

exclusive evaluation option license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: March 16, 2015. 

Richard U. Rodriguez, 

Acting Director, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2015–06486 Filed 3–20–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2); notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The purpose of this 

meeting is to evaluate requests for 

preclinical development resources for 

potential new therapeutics for the 

treatment of cancer. The outcome of the 

evaluation will provide information to 

internal NCI committees that will 

decide whether NCI should support 

requests and make available contract 

resources for development of the 

potential therapeutic to improve the 

treatment of various forms of cancer. 

The research proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the 

proposed research projects, the 

disclosure of which would constitute a 

clearly unwarranted invasion of 

personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Feb2015 

Cycle 19 NExT SEP Committee Meeting. 

Date: April 29, 2015. 

Time: 8:30 a.m. to 4:30 p.m. 

Agenda: To evaluate the NCI Experimental 

Therapeutics Program Portfolio. 

Place: National Institutes of Health, 9000 

Rockville Pike, Campus Building 31, 

Conference Room 6C10, Bethesda, MD 20892. 

Contact Persons: Barbara Mroczkowski, 

Ph.D., Executive Secretary, Discovery 

Experimental Therapeutics Program, 

National Cancer Institute, NIH, 31 Center 

Drive, Room 3A44, Bethesda, MD 20817, 

(301) 496–4291, mroczkoskib@mail.nih.gov; 

Joseph Tomaszewski, Ph.D., Executive 

Secretary, Development Experimental 

Therapeutics Program, National Cancer 

Institute, NIH, 31 Center Drive, Room 3A44, 

Bethesda, MD 20817, (301) 496–6711, 

tomaszej@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: March 17, 2015. 

Melanie J. Gray, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–06476 Filed 3–20–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Drug 

Discovery. 

Date: April 2, 2015. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Peter B. Guthrie, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4142, 

MSC 7850, Bethesda, MD 20892, (301) 435– 

1239, guthriep@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Exercise in aging, ischemia imaging. 

Date: April 2, 2015. 

Time: 12:01 p.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Samuel C. Edwards, Ph.D., 

IRG CHIEF, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 5210, MSC 7846, Bethesda, MD 

20892, (301) 435–1246, 

edwardss@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

mstockstill on DSK4VPTVN1PROD with NOTICES